ACSL1 results to be transcriptionally upregulated in both estrogen receptor (ER)-negative [62], ER-positive [63] and HER2-positive [62] breast cancer subtypes, and its mRNA levels correlate with poor patient survival [28], but the specific mechanisms and functional significance of their upregulation are unclear. The gene discussed is ACSL1; the disease is breast carcinoma.